A scan-friendly feed of peptide research, regulation, sentiment, and industry signals. Items are externally sourced and editorially filtered before they show up here.
The FDA approved orforglipron as Foundayo for adults with obesity or overweight with at least one weight-related comorbidity.
A non-injectable GLP-1 option could change adherence, access, and the competitive map around injectable incretin drugs.
FDA's Pharmacy Compounding Advisory Committee is scheduled to review several peptide-related bulk substances for possible 503A list inclusion.
This is the cleanest official signal that restricted wellness peptides may get a formal public evidence review rather than staying in rumor mode.
FDA said it did not identify a clinical need for 503B outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk substances.
This keeps pressure on bulk-compounded GLP-1 models and helps separate approved supply from gray-market access claims.
FDA reiterated when compounded GLP-1 products may be considered essentially copies and noted that semaglutide and tirzepatide are not on the 503B bulks list or shortage list.
Compounders and telehealth clinics now have less room to market copycat GLP-1 products at scale.
A phase 3 outcomes study is investigating retatrutide's effect on major cardiovascular and kidney outcomes in adults with obesity.
Outcomes trials are what move incretin candidates from weight-loss contenders to chronic disease platforms.
A non-injectable GLP-1 option could change adherence, access, and the competitive map around injectable incretin drugs.
This is the cleanest official signal that restricted wellness peptides may get a formal public evidence review rather than staying in rumor mode.
This keeps pressure on bulk-compounded GLP-1 models and helps separate approved supply from gray-market access claims.
Compounders and telehealth clinics now have less room to market copycat GLP-1 products at scale.
Outcomes trials are what move incretin candidates from weight-loss contenders to chronic disease platforms.
The peptide space is becoming a political, clinical, and commercial story at the same time.
FDA said it did not identify a clinical need for 503B outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk substances.
This keeps pressure on bulk-compounded GLP-1 models and helps separate approved supply from gray-market access claims.
Community discussion is using REDEFINE 1 to compare CagriSema against semaglutide, cagrilintide, and tirzepatide narratives.
This is the kind of noisy but useful signal that points to where comparison pages and evidence scorecards may be needed.
Axios reports that federal peptide-policy signals could create a new opening for telehealth, compounding, and longevity clinics.
The peptide space is becoming a political, clinical, and commercial story at the same time.
A recent FDA warning letter flags compounding with ineligible bulk substances, including ibutamoren mesylate and BPC-157 acetate.
Enforcement letters show how peptide policy becomes operational for pharmacies and specialty compounders.
FDA's Pharmacy Compounding Advisory Committee is scheduled to review several peptide-related bulk substances for possible 503A list inclusion.
This is the cleanest official signal that restricted wellness peptides may get a formal public evidence review rather than staying in rumor mode.
Community discussion is tracking the FDA PCAC docket and comment window for BPC-157-related bulk substances.
The official FDA docket is real, but community interpretation is already drifting toward access assumptions that need careful correction.
A new consumer-facing podcast format is packaging peptide topics into short explainers.
Media formats are catching up to search demand, and good database pages can become the deeper reference layer behind those quick explainers.
The FDA approved orforglipron as Foundayo for adults with obesity or overweight with at least one weight-related comorbidity.
A non-injectable GLP-1 option could change adherence, access, and the competitive map around injectable incretin drugs.
FDA reiterated when compounded GLP-1 products may be considered essentially copies and noted that semaglutide and tirzepatide are not on the 503B bulks list or shortage list.
Compounders and telehealth clinics now have less room to market copycat GLP-1 products at scale.
A phase 3 outcomes study is investigating retatrutide's effect on major cardiovascular and kidney outcomes in adults with obesity.
Outcomes trials are what move incretin candidates from weight-loss contenders to chronic disease platforms.
Community posts are quickly comparing oral orforglipron against injectable GLP-1 access and pricing expectations.
Approval news becomes a patient-access conversation almost immediately, especially when price and route of administration change.
A preprint reports analysis of large-scale Reddit discussion around self-reported semaglutide and tirzepatide side effects.
Social data is noisy, but it can flag patient-experience themes worth comparing against trial and pharmacovigilance data.
Lilly announced detailed ACHIEVE-3 results comparing orforglipron with oral semaglutide in adults with type 2 diabetes.
The oral GLP-1 race is now about convenience, outcomes, pricing, and direct head-to-head positioning.
TIME examines social-media interest in unapproved peptides such as BPC-157 and GHRP-2.
Mainstream attention can drive demand faster than the evidence base matures, which makes clear research framing valuable.
A longevity-focused podcast episode discusses peptides, including GLP-1s, in a broad performance and aging context.
The GLP-1 boom is pulling the wider peptide category into consumer longevity content.
A REDEFINE 1 analysis examined blood pressure changes with fixed-dose cagrilintide plus semaglutide in adults with obesity or overweight.
CagriSema is not just a weight-loss story; cardiometabolic secondary signals will shape how it is compared with tirzepatide and oral GLP-1s.
AP looks at rising interest in unapproved peptides marketed for muscle, skin, and longevity.
The public conversation is outpacing clinical evidence, creating a gap for a careful research-first database.
A phase 1 trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics for amycretin, a GLP-1 and amylin receptor agonist.
Amylin-plus-GLP-1 biology is a major direction for next-generation metabolic peptides after semaglutide and tirzepatide.
A phase 3 trial evaluated once-weekly semaglutide 2.4 mg in biopsy-defined MASH with stage 2 or 3 fibrosis.
MASH is a major expansion area for incretin drugs and a signal that metabolic peptides are competing across organ systems.
Tirzepatide received an OSA indication for adults with obesity, alongside diet and physical activity.
The GLP-1/GIP category is moving beyond weight loss into adjacent cardiometabolic and sleep-related indications.
The SURMOUNT-OSA phase 3 trials evaluated weekly tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity.
This study underpins a major label expansion and shows how obesity peptides can reshape adjacent disease categories.
The FDA approved a cardiovascular risk reduction indication for Wegovy in adults with cardiovascular disease and obesity or overweight.
This remains one of the clearest examples of GLP-1s graduating from weight-loss drugs into risk-reduction medicines.
FDA's Category 2 safety-risk page identifies BPC-157 as a bulk substance with peptide-related impurity and immunogenicity concerns.
The July PCAC review matters more because the existing FDA posture is not a simple green light for pharmacy access.
ClinicalTrials.gov lists TRIUMPH-1 as a study of retatrutide in participants with obesity or overweight.
Retatrutide remains one of the most watched next-generation incretin candidates because it adds glucagon receptor agonism to GLP-1/GIP activity.